Mita M - Search Results

1

Comparison of Large, Medium, and Small Solid Tumor Gene Panels for Detection of Clinically Actionable Mutations in Cancer.

Vail E, Song J, Xu J, Frye JS, Kim JT, Pao A, Schreck R, Aguiluz AS, Zhang W, Alkan S, Mita A, Mita M, Figlin RA, Engman DM, Lopategui JR. Vail E, et al. Among authors: mita a, mita m. Target Oncol. 2020 Aug;15(4):523-530. doi: 10.1007/s11523-020-00743-9. Target Oncol. 2020. PMID: 32770442

2

Mammalian target of rapamycin: a new molecular target for breast cancer.

Mita MM, Mita A, Rowinsky EK. Mita MM, et al. Among authors: mita a. Clin Breast Cancer. 2003 Jun;4(2):126-37. doi: 10.3816/cbc.2003.n.018. Clin Breast Cancer. 2003. PMID: 12864941 Review.

3

The molecular target of rapamycin (mTOR) as a therapeutic target against cancer.

Mita MM, Mita A, Rowinsky EK. Mita MM, et al. Among authors: mita a. Cancer Biol Ther. 2003 Jul-Aug;2(4 Suppl 1):S169-77. Cancer Biol Ther. 2003. PMID: 14508096 Review.

4

Development of rationally designed, target-based agents for the treatment of advanced colorectal cancer.

Mita AC, Mita MM, Rowinsky EK. Mita AC, et al. Among authors: mita mm. Clin Colorectal Cancer. 2004 Jul;4(2):107-23. doi: 10.3816/ccc.2004.n.014. Clin Colorectal Cancer. 2004. PMID: 15285818 Review.

5

Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics.

Mita AC, Mita MM, Nawrocki ST, Giles FJ. Mita AC, et al. Among authors: mita mm. Clin Cancer Res. 2008 Aug 15;14(16):5000-5. doi: 10.1158/1078-0432.CCR-08-0746. Clin Cancer Res. 2008. PMID: 18698017 Review.

6

Targeting the mTOR pathway using deforolimus in cancer therapy.

Mahalingam D, Sankhala K, Mita A, Giles FJ, Mita MM. Mahalingam D, et al. Among authors: mita a, mita mm. Future Oncol. 2009 Apr;5(3):291-303. doi: 10.2217/fon.09.9. Future Oncol. 2009. PMID: 19374536 Review.

7

The emerging safety profile of mTOR inhibitors, a novel class of anticancer agents.

Sankhala K, Mita A, Kelly K, Mahalingam D, Giles F, Mita M. Sankhala K, et al. Among authors: mita a, mita m. Target Oncol. 2009 Apr;4(2):135-42. doi: 10.1007/s11523-009-0107-z. Epub 2009 Apr 21. Target Oncol. 2009. PMID: 19381454 Review.

8

Targeted therapy for advanced non-small cell lung cancers: historical perspective, current practices, and future development.

Mahalingam D, Mita A, Mita MM, Nawrocki ST, Giles FJ. Mahalingam D, et al. Among authors: mita a, mita mm. Curr Probl Cancer. 2009 Mar-Apr;33(2):73-111. doi: 10.1016/j.currproblcancer.2009.03.001. Curr Probl Cancer. 2009. PMID: 19409299 Review. No abstract available.

9

Reovirus-based therapy for cancer.

Kelly K, Nawrocki S, Mita A, Coffey M, Giles FJ, Mita M. Kelly K, et al. Among authors: mita a, mita m. Expert Opin Biol Ther. 2009 Jul;9(7):817-30. doi: 10.1517/14712590903002039. Expert Opin Biol Ther. 2009. PMID: 19527106 Review.

10

The emerging role of mammalian target of rapamycin inhibitors in the treatment of sarcomas.

Vemulapalli S, Mita A, Alvarado Y, Sankhala K, Mita M. Vemulapalli S, et al. Among authors: mita a, mita m. Target Oncol. 2011 Mar;6(1):29-39. doi: 10.1007/s11523-011-0179-4. Epub 2011 Apr 28. Target Oncol. 2011. PMID: 21533543 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

459 results

Search Page

Filters